Grifols, S.A.
GRFSHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeGrifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and. The $5.27B market capitalization puts GRFS squarely in mid-cap range for its industry. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Market Cap
$5.27B
Beta
1.19
P/E (TTM)
10.06
P/E (Fwd)
5.37
EPS (TTM)
$0.77
EPS (Fwd)
$1.44
ROE
6.9%
ROA
4.2%
Cash
$537.0M
Total Debt
$9.36B
Free CF
$572.9M
52W Change
-20.8%
Annual Financials
Cash vs Debt
Where GRFS stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, GRFS finished 0.62% above its 150-day moving average ($8.04) and 1.58% below its 200-day moving average ($8.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRFS overbought or oversold?
At the August 26, 2026 close, GRFS's RSI(14) was 55.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $537.0M in cash, though total debt stands at $9.36B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $572.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 6.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $6.06B (2022) to $7.52B (2025), reflecting a 24% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Grifols, S.A.'s trajectory.